Sign in
CompletedPhase 2

Epidiolex in Obsessive Compulsive Disorder and Related Disorders

Key facts

Who runs it
University of Chicago
Where
Chicago, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
4 people enrolled
Started
14 Apr 2022
Ended
1 Nov 2025
Type of study
Interventional
Treatments tested
  • Cannabidiol
Record updated
29 July 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Men and women age 18-65
  • Primary diagnosis of OCD, Hoarding Disorder, Skin Picking Disorder, Trichotillomania, or Tourette Syndrome
  • YBOCS score of at least 18 at baseline
  • Ability to understand and sign the consent form

Who cannot take part

  • Use of any other psychotropic medication
  • Previous treatment with Epidiolex
  • Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination or labs
  • Past 12-month DSM-5 psychiatric disorder other than OCD
  • Cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent
  • Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
  • Subjects considered an immediate suicide risk based on the Columbia Suicide Severity Rating Scale (C-SSRS)
  • Illegal substance use based on urine toxicology screening
  • Initiation of psychological interventions within 3 months of screening

Where in United States

  • University of ChicagoChicago, United States

About the trial

What the trial wants to find out

The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs). Subjects will be treated in an open-label fashion with Epidiolex for two weeks.

The group in the trial

  • EpidiolexTreatment being tested

    Epidiolex (2.5 mg/kg twice daily for one week) followed by Epidiolex (5mg/kg twice daily for two weeks)

    Treatment: Cannabidiol

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study
Record updated
29 July 2026